Fidelity Investments
QNCX icon

Fidelity Investments’s Quince Therapeutics QNCX Stock Holding History

Fidelity Investments’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– -$235 – 5537
2025
Q4 		– Hold
0
– – – 5203
2025
Q2 		– Hold
0
– -$67 – 5463
2025
Q1 		– Hold
0
– – – 5138
2024
Q2 		– Sell
-8
Closed -$1.59K – 5588
2024
Q1 		$1.59K Buy
+8
New +$1.99K ﹤0.01% 4729
2022
Q3 		– Sell
-2
Closed -$1K – 5304
2022
Q2 		$1K Sell
2
-2
-50% -$1.41K ﹤0.01% 4780
2022
Q1 		$5K Buy
+4
New +$5.44K ﹤0.01% 4444
2021
Q4 		– Sell
-10
Closed -$178K – 4823
2021
Q3 		$178K Hold
10
– – ﹤0.01% 2976
2021
Q2 		$103K Hold
10
– – ﹤0.01% 3028
2021
Q1 		$70K Hold
10
– – ﹤0.01% 2980
2020
Q4 		$54K Sell
10
-2
-17% -$17.7K ﹤0.01% 2986
2020
Q3 		$122K Sell
12
-32
-73% -$291K ﹤0.01% 2762
2020
Q2 		$410K Hold
44
– – ﹤0.01% 2530
2020
Q1 		$404K Hold
44
– – ﹤0.01% 2466
2019
Q4 		$497K Hold
44
– – ﹤0.01% 2495
2019
Q3 		$221K Sell
44
-319
-88% -$1.96M ﹤0.01% 2626
2019
Q2 		$3.08M Buy
+363
New +$2.17M ﹤0.01% 2225

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Fidelity Investments's QNCX Position: Q1 2026 in Review

Fidelity Investments held its Quince Therapeutics (QNCX) position steady in Q1 2026 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5537.

Fidelity Investments first reported a position in QNCX in Q2 2019 and has held it in 13 quarters since. The position peaked at $3.08M in Q2 2019. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Fidelity Investments held 0 shares of Quince Therapeutics worth $0 as of Q1 2026.
  • Fidelity Investments left its Quince Therapeutics share count unchanged in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #5537 holding.
  • Fidelity Investments first reported a position in Quince Therapeutics in Q2 2019 and has held it in 13 quarters since.
  • Fidelity Investments's Quince Therapeutics position peaked at $3.08M in Q2 2019.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.